Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Eagle Pharmaceutical (EGRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 756,344
  • Shares Outstanding, K 13,929
  • Annual Sales, $ 213,310 K
  • Annual Income, $ 31,900 K
  • 60-Month Beta 1.67
  • Price/Sales 3.50
  • Price/Cash Flow 22.21
  • Price/Book 4.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.31
  • Number of Estimates 1
  • High Estimate 0.31
  • Low Estimate 0.31
  • Prior Year 0.17
  • Growth Rate Est. (year over year) +82.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.17 +12.72%
on 05/02/19
59.58 -8.85%
on 05/08/19
+2.58 (+4.99%)
since 04/24/19
3-Month
44.71 +21.46%
on 04/15/19
59.58 -8.85%
on 05/08/19
+8.07 (+17.46%)
since 02/22/19
52-Week
36.03 +50.71%
on 12/24/18
85.66 -36.61%
on 07/20/18
-13.00 (-19.32%)
since 05/24/18

Most Recent Stories

More News
Eagle Pharmaceuticals, Inc. to Present at 2019 RBC Capital Markets Global Healthcare Conference

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at...

EGRX : 54.30 (+1.42%)
Eagle Pharmaceut Up 29.5% Since SmarTrend Uptrend Call (EGRX)

SmarTrend identified an Uptrend for Eagle Pharmaceut (NASDAQ:EGRX) on February 21st, 2019 at $45.37. In approximately 3 months, Eagle Pharmaceut has returned 29.55% as of today's recent price of $58.77....

EGRX : 54.30 (+1.42%)
Eagle Pharmaceuticals (EGRX) Beats Q1 Earnings and Revenue Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 77.19% and 12.43%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

EGRX : 54.30 (+1.42%)
Eagle Pharmaceuticals: 1Q Earnings Snapshot

WOODCLIFF LAKE, N.J. (AP) _ Eagle Pharmaceuticals Inc. (EGRX) on Tuesday reported first-quarter earnings of $9 million.

EGRX : 54.30 (+1.42%)
Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results

-- Revised licensing agreement for BENDEKA(R) extends term of contract and increases royalty rate to 32% in 2021 --

EGRX : 54.30 (+1.42%)
Eagle Pharmaceuticals Announces Positive Results of a Study Conducted in Partnership with the U.S. Military to Evaluate Neuroprotective Effects of RYANODEX for the Treatment of Nerve Agent Exposure

-- Statistically significant robust p-values of 0.04 or less were determined in six cortical areas of the brain --

EGRX : 54.30 (+1.42%)
Eagle Pharmaceuticals (EGRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EGRX : 54.30 (+1.42%)
Eagle Pharmaceuticals to Discuss First Quarter 2019 Financial Results on May 7, 2019

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced that the Company will release its 2019 first quarter financial results on Tuesday, May 7, 2019, before...

EGRX : 54.30 (+1.42%)
New Strong Sell Stocks for April 22nd

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

GNW : 3.22 (-2.13%)
AAC : 1.10 (-15.38%)
EGRX : 54.30 (+1.42%)
GBX : 29.42 (+0.31%)
GLOG : 14.67 (+0.07%)
CMS Establishes Unique J-Code for BELRAPZO(TM) (Bendamustine 500mL Hydrochloride Injection)

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq:EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has established a unique, product-specific billing...

EGRX : 54.30 (+1.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade EGRX with:

Business Summary

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102,...

See More

Key Turning Points

2nd Resistance Point 55.78
1st Resistance Point 55.04
Last Price 54.30
1st Support Level 53.21
2nd Support Level 52.12

See More

52-Week High 85.66
Fibonacci 61.8% 66.70
Fibonacci 50% 60.85
Fibonacci 38.2% 54.99
Last Price 54.30
52-Week Low 36.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar